Somapacitan + Norditropin®

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Short Stature Children Born Small for Gestational Age (SGA)

Conditions

Short Stature Children Born Small for Gestational Age (SGA)

Trial Timeline

Jul 4, 2019 → Dec 23, 2026

NCT ID

NCT03878446

About Somapacitan + Norditropin®

Somapacitan + Norditropin® is a phase 2 stage product being developed by Novo Nordisk for Short Stature Children Born Small for Gestational Age (SGA). The current trial status is active. This product is registered under clinical trial identifier NCT03878446. Target conditions include Short Stature Children Born Small for Gestational Age (SGA).

What happened to similar drugs?

5 of 15 similar drugs in Short Stature Children Born Small for Gestational Age (SGA) were approved

Approved (5) Terminated (2) Active (10)

✅Growth HormoneEli LillyApproved

✅Somatotropin growth hormone recombinant humanPfizerApproved

✅Genotropin (somatropin)PfizerApproved

✅GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatmentPfizerApproved

✅Nutropin [Somatropin (rDNA origin) for injection]IpsenApproved

🔄somatropin + leuprorelinEli LillyPhase 3

🔄Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth HormoneAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05330325	Phase 3	Active	Aug 10, 2022	Oct 29, 2027	SGA, Turner Syndrome, Noonan Syndrome, ISS
NCT04970654	Phase 3	Completed	Jul 22, 2021	Dec 18, 2023	Growth Hormone Deficiency in Children
NCT03878446	Phase 2	Active	Jul 4, 2019	Dec 23, 2026	Short Stature Children Born Small for Gestational Age (SGA)
NCT03811535	Phase 3	Completed	May 20, 2019	Sep 30, 2025	Growth Hormone Deficiency in Children

Competing Products

20 competing products in Short Stature Children Born Small for Gestational Age (SGA)

See all competitors

Product	Company	Stage	Hype Score
somatropin + leuprorelin	Eli Lilly	Phase 3	40
Growth Hormone	Eli Lilly	Approved	35
Pancreatic Enzyme	AbbVie	Phase 2	35
Aromatase Inhibitor + Growth Hormone + Aromatase Inhibitor and Growth Hormone	AstraZeneca	Phase 3	40
Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)	Merck	Phase 1	29
Saizen® + Saizen®	Merck	Phase 3	40
r-metHuLeptin	Amgen	Phase 1	29
Somatotropin growth hormone recombinant human	Pfizer	Approved	43
Genotropin (somatropin)	Pfizer	Approved	43
Genotropin + Genotropin	Pfizer	Phase 3	40
GH treatment (Genotropin) + 1 year treatment with placebo followed by optional 3 years of GH treatment	Pfizer	Approved	43
Genotropin	Pfizer	Phase 2/3	38
glepaglutide	Zealand Pharma	Phase 3	41
Glepaglutide	Zealand Pharma	Phase 3	41
ZP1848	Zealand Pharma	Phase 2	32
glepaglutide + Placebo	Zealand Pharma	Phase 3	37
Glepaglutide	Zealand Pharma	Phase 3	37
Glepaglutide 10 mg	Zealand Pharma	Phase 3	44
Glepaglutide	Zealand Pharma	Phase 3	44
Nutropin [Somatropin (rDNA origin) for injection]	Ipsen	Approved	32